BETWEENStock Purchase Agreement • January 12th, 2009 • Air Transport Group Holdings, Inc. • Airports, flying fields & airport terminal services • Florida
RECITALSEscrow Agreement • January 12th, 2009 • Air Transport Group Holdings, Inc. • Airports, flying fields & airport terminal services
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 4th, 2020 • Pharmagreen Biotech Inc. • Airports, flying fields & airport terminal services • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 23, 2020 , by and between PHARMAGREEN BIOTECH INC., a Florida corporation, with headquarters located at 2987 Blackbear Court, Coquitlam, BC V3E 3A2, Canada (the “Company”), and GS CAPITAL PARTNERS, LLC a New York limited liability company, with its address at 30 Washington Street, Suite 5L, Brooklyn, NY 11201, (the “Buyer”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 2nd, 2022 • Pharmagreen Biotech Inc. • Airports, flying fields & airport terminal services • North Carolina
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 2, 2022, by and between PHARMAGREEN BIOTECH INC, a Nevada corporation, with its address at 2987 Blackbear Court, Coquitlam, British Columbia, CANADA (the “Company”), and JANBELLA GROUP, LLC., a North Carolina limited liability company, with its address at 20013 Chartwell Ctr. Dr. Ste. 1469, Cornelius, NC 28031 (the “Buyer”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 4th, 2020 • Pharmagreen Biotech Inc. • Airports, flying fields & airport terminal services • Nevada
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 23, 2020, is entered into by and between Pharmagreen Biotech, Inc., a Nevada corporation (the “Company”), and BHP Capital NY, Inc., a New York corporation (the “Purchaser”).
Broker-Dealer AgreementBroker-Dealer Agreement • April 14th, 2021 • Pharmagreen Biotech Inc. • Airports, flying fields & airport terminal services
This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between Pharmagreen Biotech, Inc (“Client”), a Nevada Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of March 29, 2021 (the “Effective Date”):
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 4th, 2020 • Pharmagreen Biotech Inc. • Airports, flying fields & airport terminal services • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 14, 2020, by and between PHARMAGREEN BIOTECH INC., a Nevada corporation, with headquarters located at 2987 Blackbear Court, Coquitlam, British Columbia, Canada, V3E 3A2 (the “Company”), and CROWN BRIDGE PARTNERS, LLC, a New York limited liability company, with its address at 1173a 2nd Avenue, Suite 126, New York, NY 10065 (the “Buyer”).
SUBSCRIPTION AGREEMENTSubscription Agreement • June 22nd, 2021 • Pharmagreen Biotech Inc. • Airports, flying fields & airport terminal services • Nevada
The securities of Pharmagreen Biotech Inc., a Nevada corporation (the “Company”), to which this Subscription Agreement relates, represent an investment that involves a high degree of risk, suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investments. Investors should further understand that this investment is illiquid and is expected to continue to be illiquid for an indefinite period of time.
Exhibit 10.1 Marketing and Sales Distribution Agreement NO. 2008/03 ON MARCH 6TH, 2008 Company DAQING SOLO COMPANY, LTD., hereinafter referred to as the "SELLERS", on the one part, and AZURE INTERNATIONAL, INC., hereinafter referred to as the "BUYERS"...Marketing and Sales Distribution Agreement • June 2nd, 2008 • Azure International, Inc.
SUBSCRIPTION AGREEMENTSubscription Agreement • April 14th, 2021 • Pharmagreen Biotech Inc. • Airports, flying fields & airport terminal services • Nevada
The securities of Pharmagreen Biotech Inc., a Nevada corporation (the “Company”), to which this Subscription Agreement relates, represent an investment that involves a high degree of risk, suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investments. Investors should further understand that this investment is illiquid and is expected to continue to be illiquid for an indefinite period of time.
